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T
wo groups conclude that factors near telomeres alter the telomeres’ 
nuclear positioning and thus their length.
The lengths of telomeres, which are caps for chromosome ends, 
are kept consistent by a pathway that “counts” the number of Rap1 molecules 
bound to telomeres. This pathway signals through Tel1 to recruit the lengthening 
telomerase enzyme. Cells missing Tel1 have shorter but stable telomeres, which 
argues for a second pathway regulating length. Searching for clues to the second 
pathway, Florence Hediger, Susan Gasser (Friedrich Miescher Institute, Basel, 
Switzerland), and colleagues focused on the proximity of different telomeres to 
the nuclear envelope (NE)—one place telomerase is thought to concentrate.
Her team shows that the anchoring of individual telomeres near the NE is 
variable and correlates with the composition of the subtelomeric DNA sequence 
elements (STEs). The less-anchored telomeres had two STEs with multiple binding sites for Reb1 and Tbf1, factors 
previously shown to act as insulators against telomere-associated gene silencing. Artifi  cial binding of Reb1 and 
Tbf1 to normally stably anchored telomeres can also release them from the NE.
Enter Anne-Sophie Berthiau, Eric Gilson (Ecole Normale Supérieure, Lyon, France), and colleagues. They 
showed that Reb1 and Tbf1 artifi  cially bound to subtelomeric regions causes shortening of telomeres, with more 
Reb1 and Tbf1 binding sites causing more shortening.
“Our data and Eric’s together argue that this pathway, which is not using Rap1-Tel1 signaling, may have more 
to do with proximity and accessibility of telomeres to telomerase,” says Gasser. She proposes that the binding of 
STE factors changes the folding of telomeres, and subsequently their accessibility or proximity to telomerase.
Concentrating telomerase at a membrane might keep it at a low, but effective, amount. Cells need a critical amount 
of it, but if they get too much then telomeres might get added anywhere a double-stranded DNA break occurs. 
References: Hediger, F., et al. 2006. EMBO J. doi:10.1038/sj.emboj.7600976.
Berthiau, A.-S., et al. 2006. EMBO J. doi:10.1038/sj.emboj.7600975.
K
-Ras resides at the plasma membrane (PM) where it 
promotes cell survival and proliferation. Now, Trever 
Bivona, Mark Philips (New York University, New York, 
NY), and colleagues ﬁ  nd that ﬂ  uorescent K-Ras moves to internal 
cell membranes within a few minutes after activating protein 
kinase C (PKC), with deadly consequences.
Philips’ group happened to stimulate GFP-labeled T cells 
for an unrelated experiment. “Before our eyes, K-Ras shot off 
the membrane and into the cell interior,” says Philips. K-Ras is 
attached peripherally to the PM by a farnesyl lipid group and 
an adjacent polybasic sequence. The team hypothesized that 
phosphorylation by PKC within the polybasic region acted like 
a switch, neutralizing the positive charge and releasing K-Ras 
from the PM. Indeed, blocking this serine-181 phosphorylation 
by PKC prevented K-Ras internalization.
A phosphate-mimicking Glu-181 mutant gave another 
shocking result. Cells expressing this K-Ras construct died off 
rapidly by apoptosis, as internalized K-Ras inhabited ER, Golgi, 
and—more importantly—mitochondrial membranes.
The outer mitochondrial membrane hosts apoptosis regu-
lators such as the Bcl-2 family members. Philips’ group found 
that the PKC-phosphorylated K-Ras interacted with Bcl-XL at mi-
tochondrial membranes to promote apoptosis. Human T cells 
lacking K-Ras were resistant to activation-induced apoptosis.
Although Bcl-XL is normally antiapoptotic, the group pro-
poses that K-Ras either sequesters Bcl-XL or converts it to a pro-
apoptotic molecule.
Mutated Ras proteins are known to drive uncontrolled cell 
proliferation in 30 percent of human cancers. PKC agonists may 
be a possible strategy for treating such cancers, as the group 
found that oncogenic K-Ras also moved to the mitochondria 
when phosphorylated by PKC. Furthermore, K-Ras–driven tumors 
treated with the PKC agonist bryostatin-1 underwent apoptosis. 
PKC agonists such as bryostatin “cause K-Ras to fall off the plas-
ma membrane,” says Philips, “and it goes from being a molecule 
that drives cell growth to one that kills the cell instead.” 
Reference: Bivona, T.G., et al. 2006. Mol. Cell. 21:481–493.
Telomeres (red) stay long if they are near the nuclear 
envelope (green).
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K-Ras (green) moves to mitochondria (red) when phosphorylated (right).
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